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A Therapeutic Approach to Erythrodermic Psoriasis: Report of a 
Case and a Discussion of Therapeutic Options 
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In this case report a patient with therapeutically recalcitrant 
erythrodermic psoriasis is presented . After various attempts with 
several major therapies in t his patient, the first substantia l 
improvement was achieved us ing the combination of cyclosporine 
and calcipolriol, followed by the combination of UVB and 
calcipotriol. The therapeutic options for severe psoriasis are 
discussed, and since combined approaches seem to be an attrac-
t ive alternative for severe psoriasis, mechanisms of synergy of 
combined therapeutic approaches are hypothesised. Key words: 
'·alcipotl'iol; cyclosporine; UVB; combination tllerapy. 
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Erythrodermic psoriasis is a ra re but dramatic condition. As 
a result of a trigger of any kind, psoriasis can become unstable 
a nd can extend until the whole skin is erythematous and scaly. 
ln general. systemic treatment of erythrodermic psoriasis is 
inevitable. and patients should be admiued at the inpatient 
department. 
Well-established therapeutic options for severe psoriasis, 
including erythrodermic psoriasis, are methotrexate, acitretin 
and cyclosporine. However. the therapeutic response in 
patients with erythrodermic psoriasis may be variable and 
sometimes disappointing. The search for the appropriate 
therapy is time-consuming. Often a combination of systemic 
a nd local therapies will provide the eventua l remedy for the 
patient after several weeks of in tensified supervision. 
T he aim of this report is to present a case. indicating the 
therapeutic problems during treatment of erythrodermic 
psoriasis. 
CASE REPORT 
An 83-year-old erythrodermic man was admitted to our hospital. At 
dermatological investigation generalised erythema and e:uensive scal-
ing was observed all over the body (Fig. I). face, o:calp, palms and 
soles. Histopathological investiga tion of the skin showed a chronic, 
non-specific dermatitis without signs of lymphoma or psoriasis. At 
general investigation we saw a dyspnoeic man with oedema on both 
lower legs. The body weight was 63 kg. No enlarged lymphnodes were 
palpable. No additional abnormalities were observed except for pre-
existent gallstones. Blood tests. X-thorax. ECG. CT-scan of thorax 
and abdomen, X-colon did not reveal any internal pathology. 
Especially no evidence existed for malignancy. Sentm 1.25 (OHh 
vitamin D3 and 25 OH vi tamin 0 3 were 70 pmoljl and 50 nmol/ 1. 
respectively, which was in the normal range. 
The patient had had psoriasis vulgaris for 5 years. The condition 
could be controlled up to 6 months prior to admission. A first 
exacerbation was treated with tar-UVB and calcipotriol. but 4 months 
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later, the psoriasis flared again resulting in erythroderma. The patient 
was admitted to a hospital elsewhere and was treated with potent 
topical corticosteroids such as clobetasol 17-propionate and difi'erent 
systemic therapies, each of these only for a short period. Acitretio 
had been given for 3 weeks, methotrexate for :! weeks and oral 
corticosteroids also for 2 weeks, without any substamial improvement. 
, o factors were found that could have triggered this exacerbation of 
p~oriasis. There was no history of infections or malignancy. 
As the expression of psoriasis was extremely severe and unresponsive 
to various treatments. the patient was transferred to the university 
hospital. We started therapy with acitretin (20 mg/day) and hydrocor-
tisone ( 1% in petrolatum) topically. Water-salt-balance normalised; 
furosemide 40 rug daily was given to control oedema and dyspnoea. 
Protein loss due to scaling was compensated with the appropriate diet. 
After 4 days the dose of acuretin was increased to 30 mg/day. Since 
there was no improvement, cyclosporine (3 mg/kg/day) was added 
after another 4 days. This resulted only in a minor improvement after 
3 weeks: subsequently the dose of cyclosporine was increased to 4 mgl 
kg ·day. After another week acitretin was stopped and cyclosporinc 
was again increased to 5 mgrkgtday. The skin condition in the patient 
still did not improve. Then it was decided to start local caleipotriol 
on the right side of the body whilst cont inuing cyclosporine. The 
calcipotriol-treated side showed a remarkable improvement compared 
to the other side, which was treated with bland emollients (Fig. 2). 
After I week the whole body was treated on alternate days with 
calcipotriol twice daily up to 100 g per week. On the remaining days 
of the week bland emollients were applied. As the quantity of 
calcipotriol ointment approximated 100 g per week calcium and phos-
phate in the serum were measured at weekly intervals. 
The condition of the skin improved markedly within 4 weeks. 
Meanwhile. after treatment with cyclosporine for 2 months. the serum 
creatinine increased and the patient developed a tremor of unknown 
origin. which could have been a side-effect of cyclosporine. These 
Fig. /. Erythrodcrmic skin and extensive scaling all over the body, at 
the moment of admission to hospital. 
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Fi~:. 2. Remarkable improvement on rhc righl side of rhe body. due 
10 calcipotriol on rhis side combined wirh sysremic cyclosporiue. 
symproms necessitarcd disconrinuauon of cyclosporinc. As an ahemar-
ive 10 cydosporine. phototherapy \\1lh n lo\\ dose {.;VB in combinauon 
\\ llh local calctpotriol was srartcd The rauenl responded well to rhb 
treatmem and was discharged from hosp1wl in a reasonable condiuon 
aflcr l monrh of phototherapy. Phototherapy in (;ombination \dth 
local calcipotriol was continued ut the out-pa!icn! department for 
abour 4 months. So far the condition of the parient remains excellent. 
without any psoriatic lesion up till <> months after discharge from 
ho~pital . 
During the various treatments. apart from the rransient increase of 
serum creatinine and the remporary tremor during cyclosporine. no 
side-elfccts occurred. Serum calcium and pho~phate remained in the 
normal range. 
OISCUSSI001 
Before deciding on the strategy of the treatment. the underlying 
cause of the erythroderma ha~ to be established. HisLO-
pathological investigation is not always specific (I). The 
history of a previous skin disease is an important clue to the 
diagnosis; 25% of the cases are associated with psoriasis. 
Drugs. neoplasia and eczema account for the majority of the 
other known causes. In a substantial part of the cases no 
ob\ious cause is found (2). Tn case the nosological identit) of 
the Cl') throderrna remains unkno\\ n. further internal investi-
gation is required to exclude para neoplasia ( 31. 
As erythroderma is a serious condition, fast improvement 
is urgently wanted. Topical treatments with potent cortico-
steroids may be useful: however. as the patient described in 
this report had already been treated elsewhere with potent 
corticosteroids (clobetasol17-propiomlle), a weak steroid pre-
paration was prescribed in order to prevent systemic complica-
tions. Systemic treatment is often necessary but is sometimes 
changed if no response is observed after a few days. AJso in 
the present case. various short treatments were initiated \\ ith· 
out allowing a sufficient treatment period for au anti-psoriatic 
result. One may argue that the p.!riod of 1-week acitretin 
monotherapy might have been too short to induce a significant 
tmprovemenl. However. the severity of the erythrodenna 
required a fast therapeutical effect. hence the combined 
approach. 
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Combinations of the major therapies for psoriasis are an 
auracti,·e option. since some combinations allo\\ a Jo,\er doe 
than that used in monothcrapy. v\hicb reduces side-effects. 
The combination of methotrexate and etretinate is controver-
sial in view of hepatoto:dctty ( 4.5 ): the combination of etret i-
nate and cyclosporine has been used with success in psoriasis 
( 6.7). From a theoretical point of view. the immunosuppressive 
effect of cyclosporine and !he differentiation modulating e!Tect 
of rctinoids is a promising combination. Oral retinoids 
have also been combined succc~~full) with UVB or PUVA 
(rc-PUVA) (8.9). The combination of two immunosuppressive 
therapies like methmrexate and cyclo ·porine i not recom-
mended ( 10). 
Another practical approach is the combination of systemic 
and topical therapy. After variou~ attemptS with several major 
thcrapie~ in this patient, including the combination of cyclo-
Sp()rine and acitretin, the first substantial improvemem was 
achieved using the combination or calcipot.riol and cyclospor· 
inc. In the past emollients. tars and topical steroids have been 
used in combination with systemic tht:rapies (II). Nowadays, 
the \itamin D 3 analogue calcipotriol is available. Its beneficial 
effect as a monotherap~ in mild to moderate chronic plaque 
psoriasis bas been well established (I::!). However. calcipotriol 
might irritate the skin in about 2()"·,, of tht: patients (13). In 
parucular patients with erythrodermic psoriasis are susceptible 
to lo\-\ doses of irritants. On the other hand. patients .,.. ith 
un}table and erythrodermic psoriasb have been reponed to 
rc ·pond weiJ to calcipotriol ( 14,15 ). ln the present case the 
maximum quantity of 100 g calcipotriol ointment per week 
was not exceeded. As serum vitamin 0 3 levels were nomtal. it 
w:ts excluded tl1at this patient might have had a vi tamin 0 3 
deficienc}. 
The skin is the site of production of 'itamin D3 and target 
of ns actiw metabolite: l:x.25-dih} drox)'' ita min D 3 ( 16 ). 
Vitamin 0 3 receptors. member of the steroid-hormone-
receptor super-family. are found in the epidennis ( 17 ). The 
therapeutic mode of action of \ltamm D ,, and its analogues in 
psoriasis is partly via these receptors. which regulate gene 
transcription. and partly through non-genomic mechanism~ 
( 18 ). Calcipotriol inltibits proliferation and induces terminal 
differentiation in cultured human keratinocytes ( 19). ln vil•o 
these effects a re observed as well (20). !mmunomodularing 
effects of calcipotriol are also described: inhibition ofT-cell 
proliferation in response to int.:rleukin 1 in ritro (11 l and 
reduction of interleukin 6 in a p!>oriatic plaque i11 l'ii'O in 
response to calcipotriol ( 22) 
In literature both cyclosporinc (23) and lJVB (2-U5) ha'e 
been combim:d successfully v\ith calcipotriol in psoraauc 
patit:nt:>. In particular lo\\ -Jo~e cyclosporine ( 2 mg, kg day) in 
combination with calcipotriol proved to be an effective and 
saft: approach ( 23 ). From a theoretical point of view it is 
altractive to speculate that calcipotriol-cyclosporine is a useful 
combination. The modes of action of cyclosporine and 
I :x.25-dihydroxyvitamin 0 3 and its analogues are thought to 
be complementary (26-28 ). Recently several investigators have 
demonstrated the synergistic effects of both anti-psoriatic 
therapies. Calcipotriol can potentiate the immunosuppressive 
effect of cyclosporine in mi'(tures of human lymphatic and 
epidermal cells ( 291. The effect of cyclosporine on interleukin 
2 i~ increased by calcitriol ( 26 28 ). On the other hand. the 
differential effect of both treatment~ on epidermis and immune 
system might explain the synergistic effect (30,31 ). When 
cyclo~porinc treatment wa~ not pmSJble anymore m our patient 
due to increa~e of \erum creatinine. L'VB in combination with 
calcipotrwl \\<b apphcll ~ucccssfull~ ln literature there i:. sull 
no clearnc.,~ about !l}nerg) of U\ B and calcipotnol in psona.,ts 
( 24.25 ). But the remarkable effect of the combination in thts 
patient ~ugge)t that m -.orne case:. S}nergism m1ght occur. 
In the ca~ of Cr} throdermtc r~oriasis. the therapeUtiC 
strateg) often include-. \}<.temic treatment. Options are mono-
therapy "llh acitrclln. cyclospormc o r methotrexate. The 
choice depend~ on mdications and contraindications in the 
indi-..idual patient In the present case of per)t~ung Cf) thro-
derma. combmauon thcrap} of c.;)clo~porine plus calcipotriol 
and subsequently UVB plus calcipotriol pro,ed to be a succc~s­
ful approach. 
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